Welcome to our dedicated page for MYRIAD GENETICS SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Myriad Genetics insider grant and resulting ownership: Benjamin R. Wheeler, identified as the company's Chief Financial Officer, received a grant of 60,000 time-based restricted stock units (RSUs) on 08/16/2025. The RSUs were granted at a reported price of $0 and represent contingent rights to one share of common stock each. Following the grant, the reporting person beneficially owned 95,210 shares. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. The Form 4 filing is dated 08/19/2025 and bears the signature entry by Justin Hunter on behalf of Benjamin R. Wheeler.
Benjamin R. Wheeler, identified as Chief Financial Officer and director, reported beneficial ownership of 35,210 shares of Myriad Genetics, Inc. (MYGN) in an initial Form 3 covering an event dated 08/16/2025. The filing lists Wheeler's address in Salt Lake City, UT, and includes an Exhibit 24 power of attorney. The Form 3 was signed on behalf of Wheeler by Justin Hunter on 08/19/2025.
Scott J. Leffler, listed as Chief Financial Officer and reporting person for Myriad Genetics Inc. (MYGN), filed an "Exit" Form 4 stating he is no longer serving as CFO effective August 15, 2025. The Form 4, filed August 18, 2025, reports a disposition of 218,393 shares of Common Stock (transaction code D) and indicates the filer is no longer subject to Section 16 reporting. The filing was submitted on behalf of Mr. Leffler by Justin Hunter. No derivative transactions or additional compensation details are included in this Form 4.
Myriad Genetics (MYGN) announced a change in its finance leadership: Scott J. Leffler ceased serving as Chief Financial Officer effective August 15, 2025, and Ben R. Wheeler was appointed CFO effective August 16, 2025. Mr. Wheeler, a 13-year company veteran and CPA, previously held senior finance roles including SVP, Chief Financial Officer, Operations, and SVP, Finance and Treasury. His employment agreement sets an annual base salary of $490,000, an annual target cash bonus of 75% of base salary, standard benefit participation, and an initial equity award totaling 120,000 restricted stock units (60,000 time-based, 60,000 performance/time-based). Mr. Leffler will remain as a non-executive employee briefly to assist the transition.
Disciplined Growth Investors, Inc. reports beneficial ownership of 753,956 shares of Myriad Genetics common stock, representing 0.8% of the class. The filer states it has sole voting and dispositive power over these shares and that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer. The filing identifies Myriad Genetics' principal executive offices in Salt Lake City and provides the reporting person’s Minnesota address.
Barclays PLC reported beneficial ownership of 4,899,951 shares of Myriad Genetics common stock, equal to 5.31% of the class. The filing shows Barclays has sole voting and dispositive power over 4,762,680 shares and shared voting and dispositive power over 137,271 shares. The reporting person is classified as HC and the filing identifies related subsidiaries as Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
This document is a Schedule 13G disclosure and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence the control of the issuer.